Sherilyn A. Tuazon

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Tanya Siddiqi, David G. Maloney, Saad S. Kenderian et al. · The Lancet · 2023 · 174 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Transcend Cll 004 +9

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Damian J. Green, Margot J. Pont, Blythe Sather et al. · Blood · 2018 · 129 citations

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

Andrew J. Cowan, Margot J. Pont, Blythe Sather et al. · The Lancet Oncology · 2023 · 87 citations · Full text

Hematological Malignancy, Cancer Immunosurveillance, Immunology +10

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, Margot J. Pont, Blythe Sather et al. · Blood · 2019 · 63 citations

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Shyril O’Steen, Melissa L. Comstock, Johnnie J. Orozco et al. · Blood · 2019 · 54 citations · Full text